Molecular Weight(MW): 362.46
Hydrocortisone is a steroid hormone or glucocorticoid produced by the adrenal gland.
Purity & Quality Control
Choose Selective Glucocorticoid Receptor Inhibitors
|Description||Hydrocortisone is a steroid hormone or glucocorticoid produced by the adrenal gland.|
Hydrocortisone prevents endothelial barrier breakdown in response to pro-inflammatory stimuli (TNFalpha administration) in the human brain microvascular endothelial cell line hCMEC/D3, which could be demonstrated to be partly based on maintenance of occludin levels.  Hydrocortisone-treated dendritic cells (DCs) show a decreased expression of MHC II molecules, the costimulatory molecule CD86, and the DC-specific marker CD83, as well as a strongly reduced IL-12 secretion. Hydrocortisone-treated DCs inhibits production of IFN-gamma but induces an increased release of IL-4 and no change in IL-5. Hydrocortisone reduces T-cell proliferation in dendritic cells.  Hydrocortisone prevents TNF-alpha induced severe degradation of the glycocalyx, increased coronary resistance, heightened vascular leak and permeability to hydroxyethyl starch and caused mast-cell degranulation in isolated guinea pig hearts.  Hydrocortisone reduces postischemic oxidative stress, perfusion pressure, and transudate formation in isolated guinea pig hearts. Hydrocortisone inhibits postischemic shedding of syndecan-1, heparan sulfate, and hyaluronan, as well as release of histamine from resident mast cells.  Hydrocortisone increases the levels of IL-4-induced germ line C epsilon transcripts by twofold and delivers the signal required for transcription of mature C epsilon mRNA. Hydrocortisone induces S mu-S epsilon deletional switch recombination in IL-4-treated B cells, and support a model of sequential isotype switching from IgM to IgE via IgG4. 
-  F鰎ster C, et al. J Physiol, 2008, 586(7), 1937-1949.
-  Bellinghausen I, et al. J Allergy Clin Immunol, 2001, 108(2), 242-249.
-  Chappell D, et al. Basic Res Cardiol, 2009, 104(1), 78-89.
|In vitro||DMSO||73 mg/mL (201.4 mM)|
|Ethanol||23 mg/mL (63.45 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT01859312||Completed||Adrenal Insufficiency|Excess Androgen|Congenital Adrenal Hyperplasia (CAH)||National Institutes of Health Clinical Center (CC)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||May 6, 2013||Phase 2|
|NCT00097474||Completed||Jet Lag Syndrome||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)||November 22, 2004||Phase 2|
|NCT03007147||Not yet recruiting||B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia||Childrens Oncology Group|National Cancer Institute (NCI)||July 2017||Phase 3|
|NCT01422733||Not yet recruiting||Hyperandrogenemia|Obesity|Polycystic Ovary Syndrome||University of Virginia||April 2017||--|
|NCT01422707||Not yet recruiting||Hyperandrogenemia|Obesity|Polycystic Ovary Syndrome||University of Virginia||April 2017||--|
|NCT03020030||Not yet recruiting||Acute Lymphoblastic Leukemia, Pediatric||Dana-Farber Cancer Institute|Baxalta US Inc.||January 2017||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.